A bi-steric mTORC1-selective inhibitor overcomes drug resistance in breast cancer

Activation of the PI3K-mTOR pathway is central to breast cancer pathogenesis including resistance to many targeted therapies. The mTOR kinase forms two distinct complexes, mTORC1 and mTORC2, and understanding which is required for the survival of malignant cells has been limited by tools to selectiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Meng, Delong, Zhao, Xin, Yang, Yu Chi, Navickas, Albertas, Helland, Ciara, Goodarzi, Hani, Singh, Mallika, Bandyopadhyay, Sourav
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10328828/
https://www.ncbi.nlm.nih.gov/pubmed/37264081
http://dx.doi.org/10.1038/s41388-023-02737-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10328828/
https://www.ncbi.nlm.nih.gov/pubmed/37264081
http://dx.doi.org/10.1038/s41388-023-02737-z

Ejemplares similares